Bibliographic Details
| Title: |
There is No Distinctive Gut Microbiota Signature in the Metabolic Syndrome: Contribution of Cardiovascular Disease Risk Factors and Associated Medication |
| Authors: |
Adrián Cortés-Martín, Carlos E. Iglesias-Aguirre, Amparo Meoro, María Victoria Selma, Juan Carlos Espín |
| Source: |
Microorganisms, Vol 8, Iss 3, p 416 (2020) |
| Publisher Information: |
MDPI AG, 2020. |
| Publication Year: |
2020 |
| Collection: |
LCC:Biology (General) |
| Subject Terms: |
gut microbiota, metabolic syndrome, obesity, cardiovascular risk, drug treatment, diabetes, dyslipidemia, hypertension, precision medicine, Biology (General), QH301-705.5 |
| More Details: |
The gut microbiota (GM) has attracted attention as a new target to combat several diseases, including metabolic syndrome (MetS), a pathological condition with many factors (diabetes, obesity, dyslipidemia, hypertension, etc.) that increase cardiovascular disease (CVD) risk. However, the existence of a characteristic taxonomic signature associated with obesity-related metabolic dysfunctions is under debate. To investigate the contribution of the CVD risk factors and(or) their associated drug treatments in the composition and functionality of GM in MetS patients, we compared the GM of obese individuals (n = 69) vs. MetS patients (n = 50), as well as within patients, depending on their treatments. We also explored associations between medication, GM, clinical variables, endotoxemia, and short-chain fatty acids. Poly-drug treatments, conventional in MetS patients, prevented the accurate association between medication and GM profiles. Our results highlight the heterogeneity of taxonomic signatures in MetS patients, which mainly depend on the CVD risk factors. Hypertension and(or) its associated medication was the primary trait involved in the shaping of GM, with an overabundance of lipopolysaccharide-producing microbial groups from the Proteobacteria phylum. In the context of precision medicine, our results highlight that targeting GM to prevent and(or) treat MetS should consider MetS patients more individually, according to their CVD risk factors and associated medication. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2076-2607 |
| Relation: |
https://www.mdpi.com/2076-2607/8/3/416; https://doaj.org/toc/2076-2607 |
| DOI: |
10.3390/microorganisms8030416 |
| Access URL: |
https://doaj.org/article/a42529a449ec4310b565a71925caab60 |
| Accession Number: |
edsdoj.42529a449ec4310b565a71925caab60 |
| Database: |
Directory of Open Access Journals |
